Single-blind, Randomized, Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001457-18

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the immunogenicity of 60 ?g, 120 µg and 200 ?g of rLP2086 as measured by serum bactericidal assay (SBA) to MnB strains expressing LP2086 subfamily A and B proteins in healthy infants 1 month after the infant series.


Critère d'inclusion

  • Healthy infant vaccination against Meningitis B

Liens